Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway

References

• Pinna LA. The oncogenic potential of CK2. John Wiley & Sons, Inc. 2013; 10.
   Google Scholar
• Xu X, Landesman-Bolliag E, Channavajhala PL, et al. Murine protein kinase CK2: gene and oncogene. Mol Cell Biochem. 1999;191:65–74.
   PubMed Web of Science ®Google Scholar
• Bibby AC, Litchfield DW. The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2β. Int J Biol Sci. 2005;1:67–79.
   PubMed Web of Science ®Google Scholar
• Trembley JH, Chen Z, Unger G, et al. Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors. 2010;36:187–195.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang H, Wang J, et al. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: A computational study. Int J Mol Sci. 2011;12:7004–7021.
   PubMed Web of Science ®Google Scholar
• Manni S, Carrino M, Piazza F. Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways. J Hematol Oncol. 2017;10:157.
   PubMed Web of Science ®Google Scholar
• Chua M, Lee M, Dominguez I. Cancer-type dependent expression of CK2 transcripts. Plos One. 2017;12:e0188854.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Y, Mao JH, et al. Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. Plos One. 2012;7:e38996.
   PubMed Web of Science ®Google Scholar
• Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci. 2009;66:1858–1867.
   PubMed Web of Science ®Google Scholar
• Di MG, Salvi M, Arrigoni G, et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 2005;12:668–677.
   PubMed Web of Science ®Google Scholar
• Park JH, Kim JJ, Bae YS. Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells. Biochem Biophys Res Commun. 2013;433:420–425.
   PubMed Web of Science ®Google Scholar
• Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276:993–998.
   PubMed Web of Science ®Google Scholar
• Seldin DC. New models of lymphoma in transgenic mice. Curr Opin Immunol. 1995;7:665–673.
   PubMed Web of Science ®Google Scholar
• Landesmanbollag E, Song DH, Romieumourez R, et al. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem. 2001;227:153–165.
   PubMed Web of Science ®Google Scholar
• Agarwal M, Nitta RT, Li G. Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells. J Mol Genet Med. 2014;8:pii:1000094.
   Google Scholar
• Bennetzen MV, Larsen DH, Bunkenborg J, et al. Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics. 2010;9:1314–1323.
   PubMed Web of Science ®Google Scholar
• Zhang HX, Jiang SS, Zhang XF, et al. Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. Oncotarget. 2015;6:34800–34817.
   PubMedGoogle Scholar
• Siddiquijain A, Bliesath J, Macalino D, et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther. 2012;11:994–1005.
   PubMed Web of Science ®Google Scholar
• Adam SJ, Denis D, Nicole S, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010;70:10288–10298.
   PubMed Web of Science ®Google Scholar
• Eliseeva IA, Kim ER, Guryanov SG, et al. YB-1 and its functions. Biochemistry (Mosc). 2011;76:1402–1433.
   PubMed Web of Science ®Google Scholar
• Kohno K, Izumi HT, Ashizuka M, et al. The pleiotropic functions of the Y-box-binding protein, YB-1. Bio Essays. 2003;25:691–698.
   PubMed Web of Science ®Google Scholar
• Kuwano M, Oda Y, Izumi H, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004;3:1485–1492.
   PubMed Web of Science ®Google Scholar
• Habibi G, Leung S, Law JH, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008;10:R86.
   PubMed Web of Science ®Google Scholar
• Sperling O, Brosh S, De VA. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005;65:4078–4087.
   PubMed Web of Science ®Google Scholar
• Sutherland BW, Kucab J, Wu J, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24:4281–4292.
   PubMed Web of Science ®Google Scholar
• Stratford AL, Fry CJ, Desilets C, et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008;10:R99.
   PubMed Web of Science ®Google Scholar
• To K, Fotovati A, Reipas KM, et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010;70:2840–2851.
   PubMed Web of Science ®Google Scholar
• Astanehe A, Finkbeiner MR, Hojabrpour P, et al. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene. 2009;28:2406–2418.
   PubMed Web of Science ®Google Scholar
• Finkbeiner MR, Astanehe A, To K, et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene. 2009;28:1421–1431.
   PubMed Web of Science ®Google Scholar
• Bargou RC, Jürchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;26:447–450.
   Google Scholar
• Chatterjee M, Rancso C, Stühmer T, et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood. 2008;111:3714–3722.
   PubMed Web of Science ®Google Scholar
• Lee C, Dhillon J, Wang MY, et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008;68:8661–8666.
   PubMed Web of Science ®Google Scholar
• Shibao K, Takano HY, Okazaki K, et al. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer. 1999;83:732–737.
   PubMed Web of Science ®Google Scholar
• Vaiman AV, Stromskaya TP, Rybalkina EY, et al. Development of drug resistance in the population of colon cancer cells under the effect of multifunctional protein YB-1. B Exp Biol Med. 2007;143:463–466.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Lasham A, Print CG, Woolley AG, et al. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J. 2013;449:11–23.
   PubMed Web of Science ®Google Scholar
• Evdokimova V, Ruzanov P, Anglesio MS, et al. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Cell Mol Biol Lett. 2006;26:277–292.
   Google Scholar
• Shiraiwa S, Kinugasa T, Kawahara A, et al. Nuclear Y-Box-binding protein-1 expression predicts poor clinical outcome in stage III colorectal cancer. Anticancer Res. 2016;36:3781–3788.
   PubMed Web of Science ®Google Scholar
• Siddiquijain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010;70:10288–10298.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001;1:63–72.
   PubMed Web of Science ®Google Scholar
• Janus JM, Rfl OS, Harwood CA, et al. Phosphoinositide 3-kinase-dependent signalling pathways in cutaneous squamous cell carcinomas. Cancers (Basel). 2017;9:86–134.
   Web of Science ®Google Scholar
• Mantamadiotis T. Towards targeting PI3K-dependent regulation of gene expression in brain cancer. Cancers (Basel). 2017;9:60.
   PubMed Web of Science ®Google Scholar
• Crumbaker M, Khoja L, Joshua AM. AR signaling and the PI3K pathway in prostate cancer. Cancers (Basel). 2017;9:34.
   PubMed Web of Science ®Google Scholar
• Piddock RE, Bowles KM, Rushworth SA. The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma. Cancers (Basel). 2017;9:29.
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Kuroda H, Takahashi R, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137:173–179.
   PubMed Web of Science ®Google Scholar
• Pinna LA. 12. CK2 Suppression of apoptosis and its implication in cancer biology and therapy. John Wiley & Sons, Inc. 2013;12:319–343.
   Google Scholar
• Prabhu L, Mundade R, Wang B, et al. Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer. Oncotarget. 2015;6:29396–29412.
   PubMedGoogle Scholar
• Melão A, Spit M, Cardoso BA, et al. Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity. Haematologica. 2016;101:1368–1379.
   PubMed Web of Science ®Google Scholar
• Cirigliano SM, Díaz Bessone MI, Berardi DE, et al. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines. Cancer Cell Int. 2017;17:42.
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–1167.
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287–290.
   PubMed Web of Science ®Google Scholar
• Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood. 2008;112:2463–2473.
   PubMed Web of Science ®Google Scholar
• Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A. 2009;106:19503–19508.
   PubMed Web of Science ®Google Scholar